- Home
- SRTS vs ABOS Comparison
SRTS vs ABOS Comparison
Compare SRTS & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- ABOS
- Stock Information
- Founded
- SRTS 2010
- ABOS 1996
- Country
- SRTS United States
- ABOS United States
- Employees
- SRTS N/A
- ABOS N/A
- Industry
- SRTS Medical/Dental Instruments
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- ABOS Health Care
- Exchange
- SRTS Nasdaq
- ABOS Nasdaq
- Market Cap
- SRTS 75.5M
- ABOS 90.3M
- IPO Year
- SRTS 2016
- ABOS 2021
- Fundamental
- Price
- SRTS $5.33
- ABOS $1.38
- Analyst Decision
- SRTS Strong Buy
- ABOS Strong Buy
- Analyst Count
- SRTS 3
- ABOS 3
- Target Price
- SRTS $11.67
- ABOS $6.33
- AVG Volume (30 Days)
- SRTS 134.3K
- ABOS 577.8K
- Earning Date
- SRTS 08-07-2025
- ABOS 08-15-2025
- Dividend Yield
- SRTS N/A
- ABOS N/A
- EPS Growth
- SRTS N/A
- ABOS N/A
- EPS
- SRTS 0.11
- ABOS N/A
- Revenue
- SRTS $39,488,000.00
- ABOS N/A
- Revenue This Year
- SRTS $4.33
- ABOS N/A
- Revenue Next Year
- SRTS $26.74
- ABOS N/A
- P/E Ratio
- SRTS $47.72
- ABOS N/A
- Revenue Growth
- SRTS 24.75
- ABOS N/A
- 52 Week Low
- SRTS $4.01
- ABOS $0.86
- 52 Week High
- SRTS $9.33
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- SRTS 57.88
- ABOS 50.53
- Support Level
- SRTS $5.21
- ABOS $1.29
- Resistance Level
- SRTS $5.92
- ABOS $1.41
- Average True Range (ATR)
- SRTS 0.39
- ABOS 0.11
- MACD
- SRTS 0.04
- ABOS -0.03
- Stochastic Oscillator
- SRTS 63.80
- ABOS 19.39
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.